Procalcitonin vs C-reactive protein as predictive markers of response to antibiotic therapy in acute exacerbations of COPD

Chest

Volumn 138, Issue 5, 2010, Pages 1108-1115

  Daniels, Johannes M A ^a   Schoorl, Marianne ^a   Snijders, Dominic ^a   Knol, Dirk L ^b   Lutter, René ^c   Jansen, Henk M ^c   Boersma, Wim G ^a  

^a Location Alkmaar   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CORTICOSTEROID; DOXYCYCLINE; PROCALCITONIN;

AGED; ANTIBIOTIC THERAPY; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CORRELATION ANALYSIS; DISEASE EXACERBATION; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 78349254261     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.09-2927     Document Type: Article

References (25)

1. Murray CJ, Lopez AD. Evidence-based health policy - lessons from the Global Burden of Disease Study. Science. 1996;274(5288):740-743.
2. Seemungal TA, Donaldson GC, Bhowmik A, Jeffries DJ, Wedzicha JA. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2000;161(5):1608-1613.
3. Fletcher CM, Peto R, Tinker CM, et al. Natural History of Chronic Bronchitis and Emphysema. Oxford, England : Oxford University Press; 1976.
4. White AJ, Gompertz S, Stockley RA. Chronic obstructive pulmonary disease. 6: the aetiology of exacerbations of chronic obstructive pulmonary disease. Thorax. 2003;58(1):73-80.
5. Ram FS, Rodriguez-Roisin R, Granados-Navarrete A, Garcia-Aymerich J, Barnes NC. Antibiotics for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2006;19(2):CD004403.
6. Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med. 1987;106(2):196-204.
7. World Health Organization (WHO). WHO Report on Infectious Disease: Overcoming Antimicrobial Resistance. Geneva, Switzerland: WHO; 2000.
8. Simon L, Gauvin F, Amre DK, Saint-Louis P, Lacroix J. Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin Infect Dis. 2004;39(2):206-217.
9. Stolz D, Christ-Crain M, Bingisser R, et al. Antibiotic treatment of exacerbations of COPD: a randomized, controlled trial comparing procalcitonin-guidance with standard therapy. Chest. 2007;131(1):9-19.
10. Hurst JR, Donaldson GC, Perera WR, et al. Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2006;174(8):867-874.
11. Weis N, Almdal T. C-reactive protein - can it be used as a marker of infection in patients with exacerbation of chronic obstructive pulmonary disease? Eur J Intern Med. 2006;17(2):88-91.
12. Gompertz S, O'Brien C, Bayley DL, Hill SL, Stockley RA. Changes in bronchial inflammation during acute exacerbations of chronic bronchitis. Eur Respir J. 2001;17(6):1112-1119.
13. Dev D, Wallace E, Sankaran R, et al. Value of C-reactive protein measurements in exacerbations of chronic obstructive pulmonary disease. Respir Med. 1998;92(4):664-667.
14. Daniels JM, Snijders D, de Graaff CS, et al. Antibiotics in addition to systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2010;181(2):150-157.
15. Chow AW, Hall CB, Klein JO, Kammer RB, Meyer RD, Remington JS; Infectious Diseases Society of America and the Food and Drug Administration. Evaluation of new anti-infective drugs for the treatment of respiratory tract infections. Clin Infect Dis. 1992;15(Suppl 1):S62-S88.
16. Isenberg HD. Clinical Microbiology Procedures Handbook. Washington, DC: American Society for Microbiology; 1992.
17. Becker KL, Snider R, Nylen ES. Procalcitonin assay in systemic inflammation, infection, and sepsis: clinical utility and limitations. Crit Care Med. 2008;36(3):941-952.
18. Niederman MS. Biological markers to determine eligibility in trials for community-acquired pneumonia: a focus on procalcitonin. Clin Infect Dis. 2008;47(Suppl 3):S127-S132.
19. Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest. 2003;111(12):1805-1812.
20. Bozinovski S, Hutchinson A, Thompson M, et al. Serum amyloid a is a biomarker of acute exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2008;177(3):269-278.
21. Rohde G, Borg I, Wiethege A, et al. Inflammatory response in acute viral exacerbations of COPD. Infection. 2008;36(5):427-433.
22. Sethi S, Wrona C, Eschberger K, Lobbins P, Cai X, Murphy TF. Inflammatory profile of new bacterial strain exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2008;177(5):491-497.
23. McCrory DC, Brown C, Gelfand SE, Bach PB. Management of acute exacerbations of COPD: a summary and appraisal of published evidence. Chest. 2001;119(4):1190-1209.
24. Saint S, Bent S, Vittinghoff E, Grady D. Antibiotics in chronic obstructive pulmonary disease exacerbations. A meta-analysis. JAMA. 1995;273(12):957-960.
25. van der Eerden MM, de Graaff CS, Vlaspolder F, Bronsveld W, Jansen HM, Boersma WG. Evaluation of an algorithm for switching from IV to PO therapy in clinical practice in patients with community-acquired pneumonia. Clin Ther. 2004;26(2):294-303.